Anti-Necrotic organ preservation program
exploratoryresearch program · high · Tue Apr 14 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Improve organ preservation viability and equity in transplantation using Anti-Necrotic technology.
Anti-Necrotic technology applied to organ preservation.
UKRI/Gateway to Research record lists project 'Revolutionising Organ Preservation: Innovative Anti-Necrotic Technology for Enhanced Viability and Equity in Transplantation' with LinkGevity as lead participant, project cost £333,416 and grant offer £233,392.
Revolutionising Organ Preservation anti-necrotic project
preclinicalresearch program · high · Tue Apr 14 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Enhance organ viability and equity in transplantation through anti-necrotic organ preservation technology.
Anti-Necrotic technology applied to organ preservation.
UKRI Gateway to Research record lists LinkGevity Limited as lead participant with project cost GBP 333,416 and grant offer GBP 233,392.
Anti-Necrotic kidney disease and aging-related degeneration program
phase 2drug program · medium · Sun Nov 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop a first-in-class necrosis inhibitor targeting cellular degeneration for kidney disease, aging-related degeneration, and potential aging indications.
Anti-Necrotic necrosis-inhibitor therapeutic; described as a first-in-class intervention for kidney disease and aging-related degeneration.
Reported as ready to begin Phase II clinical trials later in 2025; also selected for NASA/TRISH Space-Health consideration as one of 12 global technologies.
Anti-Necrotic therapy for kidney disease and ageing-related degeneration
phase 2drug program · high · Sun Nov 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop a first-in-class necrosis inhibitor targeting cellular degeneration as a potential treatment for kidney disease and ageing-related degeneration, including acute kidney injury and broader resilience loss.
Anti-Necrotic necrosis-inhibitor therapeutic developed from LinkGevity's AI-powered Blueprint Theory/Blueprint Maps approach.
Reported as ready to begin Phase II clinical trials later in 2025; also selected for NASA/TRISH Space-Health program as one of 12 global innovations.
Anti-Necrotic therapy in space biology program
exploratoryresearch program · medium · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate Anti-Necrotic therapy for space-related biological stressors, including accelerated aging, kidney dysfunction, and resilience loss during long-duration missions.
Application of LinkGevity's Anti-Necrotic intervention to space-health and microgravity/radiation-related biology.
Company site reports UK Space Agency funding to advance Anti-Necrotic therapy in space; supplied publication states the technology caught the attention of NASA HRP and TRISH's Space-Health Program.
Future GLP-1-type systemic therapeutics research
exploratoryresearch program · medium · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Explore how GLP-1-type systemic therapeutics could reshape aging and medicine beyond obesity treatment.
Published research/editorial analysis using a blueprint/systemic therapeutics framing.
2025 publication titled 'Beyond GLP-1s: The blueprint for systemic therapeutics that will reshape aging and medicine'.
Acute tubular necrosis anti-necrotic program
preclinicaldrug program · medium
Address acute tubular necrosis, a leading cause of kidney dysfunction.
Anti-Necrotic technology focused on acute tubular necrosis.
March 2025 press coverage cited an Innovate UK Smart Grant for a one-year project involving LinkGevity's Anti-Necrotic technology around acute tubular necrosis.
Anti-necrotic applications for tissue engineering and cell culture
exploratoryresearch program · medium
Apply anti-necrotic approaches to tissue engineering and cell culture applications.
Anti-Necrotic technology targeting necrosis in tissue engineering and cell culture contexts.
Identified in supplied site analysis as an application area for LinkGevity's lead Anti-Necrotic programs.
Anti-Necrotic applications in tissue engineering, organ preservation, and lab reagents
exploratoryresearch program · medium
Explore non-clinical uses of Anti-Necrotics in tissue engineering, organ preservation, and laboratory reagents.
Application of necrosis-inhibitor technology to non-clinical biological preservation and tissue-engineering contexts.
Non-clinical application areas identified in company description.
Anti-Necrotic laboratory reagents applications
exploratoryother · low
Develop or use Anti-Necrotic technology as lab reagents for non-clinical applications.
Non-clinical lab reagent application of Anti-Necrotics.
Listed in supplied company analysis as a non-clinical application area for Anti-Necrotics.
Anti-Necrotic therapy for kidney disease and aging-related degeneration
preclinicaldrug program · high
Develop a potential first-in-class intervention for kidney disease and aging-related degeneration by targeting necrosis.
Anti-Necrotic therapeutic intervention intended to mitigate necrosis-related degeneration.
Described in 2025 publication material as supported in part by Horizon Europe and Innovate UK, and as having attracted attention from NASA HRP and TRISH's Space-Health Program.
Anti-Necrotic therapy in space
exploratoryresearch program · high
Advance anti-necrotic therapy for biological challenges of spaceflight and potential terrestrial healthspan applications.
Space biology research applying anti-necrotic intervention concepts to microgravity, radiation, kidney dysfunction, and aging-related degeneration contexts.
LinkGevity announced UK Space Agency funding in 2025 to advance Anti-Necrotic therapy in space.
Anti-Necrotic therapy in space biology
exploratoryresearch program · medium
Evaluate Anti-Necrotic therapy for mitigating accelerated ageing, necrosis, kidney dysfunction, and other biological risks during long-duration space missions.
Space-health research application of LinkGevity's necrosis-inhibitor therapeutic, supported by UK Space Agency funding and NASA/TRISH Space-Health program selection.
UK Space Agency funding reported in 2025 to advance Anti-Necrotic therapy in space; technology selected for NASA/TRISH Space-Health program.
Anti-Necrotic tissue engineering applications
exploratoryresearch program · low
Apply Anti-Necrotic necrosis inhibition to tissue engineering use cases.
Non-clinical use of Anti-Necrotics in tissue engineering.
Listed in supplied company analysis as a non-clinical application area for Anti-Necrotics.
Blueprint Maps AI drug discovery platform
undisclosedplatform · high
Identify biological triggers of aging and therapeutic targets for age-related disease.
AI-driven semantic processing and proprietary Blueprint Maps based on LinkGevity's Blueprint Theory of aging.
Platform described publicly as the basis for LinkGevity's anti-necrotic therapeutic discovery work.
LINK-001
undiscloseddrug program · medium
Undisclosed anti-necrotic therapeutic program in LinkGevity's public pipeline.
Anti-Necrotic therapy program; specific intervention method not disclosed in the supplied material.
Listed in LinkGevity's public pipeline.
LINK-002
undiscloseddrug program · medium
Undisclosed anti-necrotic therapeutic program in LinkGevity's public pipeline.
Anti-Necrotic therapy program; specific intervention method not disclosed in the supplied material.
Listed in LinkGevity's public pipeline.
LINK-002 undisclosed pipeline program
undiscloseddrug program · low
Undisclosed LinkGevity pipeline program; specific indication and objective not provided in the supplied material.
Undisclosed; listed as part of LinkGevity's pipeline alongside Anti-Necrotics programs.
Listed on LinkGevity pipeline page.
LINK-003
undiscloseddrug program · medium
Undisclosed anti-necrotic therapeutic program in LinkGevity's public pipeline.
Anti-Necrotic therapy program; specific intervention method not disclosed in the supplied material.
Listed in LinkGevity's public pipeline.
LINK-003 undisclosed pipeline program
undiscloseddrug program · low
Undisclosed LinkGevity pipeline program; specific indication and objective not provided in the supplied material.
Undisclosed; listed as part of LinkGevity's pipeline alongside Anti-Necrotics programs.
Listed on LinkGevity pipeline page.
LINK-004
undiscloseddrug program · medium
Undisclosed anti-necrotic therapeutic program in LinkGevity's public pipeline.
Anti-Necrotic therapy program; specific intervention method not disclosed in the supplied material.
Listed in LinkGevity's public pipeline.
LINK-004 undisclosed pipeline program
undiscloseddrug program · low
Undisclosed LinkGevity pipeline program; specific indication and objective not provided in the supplied material.
Undisclosed; listed as part of LinkGevity's pipeline alongside Anti-Necrotics programs.
Listed on LinkGevity pipeline page.
Systemic GLP-1-type therapeutics research
exploratoryresearch program · medium
Investigate or articulate future systemic therapeutics inspired by GLP-1-type drugs that may reshape ageing and medicine beyond obesity treatment.
Publication-led research and therapeutic framework discussing GLP-1 receptor agonists and systemic drug effects in ageing and medicine.
2025 publication titled "Beyond GLP-1s: The blueprint for systemic therapeutics that will reshape aging and medicine" listed among LinkGevity-related publications.
